DGPPN 2018 Programm

POSTERPRÄSENTATIONEN 202 MITTWOCH DONNERSTAG FREITAG SAMSTAG 005 A unified pre-analytical protocol for handling of CSF samples before analyses of AD biomarker levels Manfred Uhr, München Oskar Hansson, Richard Batrla-Utermann, Ekaterina Bauer, Nadja Baur-Kolarov, Britta Brix, Maria C Carrillo, Veronika Corradini, Robert Dean, Udo Eichenlaub, Christina Hall, James Hendrix, John Lawson, Valeria Lifke, José Luis Molineuvo, Sandra Rutz, Salvatore Salamone, Christopher Traynham, Robert Umek, Simone Wahl, Hugo Vanderstichele, Manu Vandijck, Kai Blennow 006 Predicting future dementia: the role of white-matter integrity Theresa Müller, Köln Nicola M. Payton, Grégoria Kalpouzos, Martin Lövdén, Laura Fratiglioni, Lars Bäckman, Erika Jonsson Laukka 007 Predicting verbal episodic memory changes with measures of brain atrophy: a longitudinal approach in patients with mild cognitive impairment Katharina Klink, Bern (Schweiz) Ahmed Abdulkadir, Lora Minkova, Michel Grothe, Stefan Teipel, Lena Schumacher, Christoph Kaller, Jacob Lahr, Stefan Klöppel, Jessica Peter 008 Connectome genetics reveal neuro- psychiatric brain phenotypes in thyroid hormone transporter deficiency Jonathan Reinwald, Mannheim Alexander Sartorius, Wolfgang Weber-Fahr, Heike Heuer, Thomas Münte 009 Individualised assessment of efficacy and prediction of outcomes of treatment with Cerebrolysin by machine learning: a new design of the controlled before-and-after study Vitalij Kazin, Kaufbeuren Alexandr Merkin, Igor Nikiforov, Andrew Storokha, Igor Dorovskikh, William Caicedo, Georgy Kostiuk, Dmitry Savelyev, Nikola Kasabov, Valery Feigin 010 Approaching therapy of Alzheimer's disease via antidiabetic drug liraglu- tide – hippocampal neurogenesis and cerebral energy metabolism-related gene expression in an experimental rat model of sporadic Alzheimer's Michael Jürgen Hosch, Würzburg Ana Knezovic, Sandy Popp, Gabriela Ortega y Schulte, Catharina Hamann, Jelena Osmanovic-Barilar, Emanuela Corradino, Melita Salkovic-Petrisic, Angelika Schmitt- Böhrer 011 Chronic 9-Tetrahydrocannabinol treatment rescues behavior deficits in the 5XFAD familial Alzheimer's mouse model Jannek Moritz Wagner, Göttingen Eva Maria Schleicher, Jens Wiltfang, Thomas A. Bayer, Yvonne Bouter 012 Individual vs. health-related qual- ity of life in patients with idiopathic Parkinson's disease, measured with the Schedule for Evaluation of Individual Quality of Life and Parkinson's disease questionnaire Karolina Nowak, Basel (Schweiz) Antonia Meyer, Ivana Handabaka, Peter Fuhr, Ute Gschwandtner P-23 (e) Postersitzung 13:30– 15:00 Uhr | Saal Helsinki 1 /2 TOPIC 2: Psychische Störungen durch psychotrope Substanzen, Verhaltenssüchte, F1 Addictive disorders Vorsitz: Norbert Wodarz, Regensburg 001 The relationship between neuro- physiological correlates of inhibitory control and disorder severity in patients with alcohol use disorders – preliminary results Hallie Batschelet, Bern (Schweiz) Raphaela Martina Tschümperlin, Franz Moggi, Leila Soravia, Thomas König, Susanne Rösner, Anne Keller, Alexander Wopfner, Maria Stein